Earnings call transcript: Lonza misses Q4 2025 forecasts, stock drops 9%

Endpoints NewsInside Makary’s ouster; Another win for Lilly’s triple-G; and more

10x Genomics BlogSerge Saxonov (TXG) reports multiple 2026 sales and a 35,270-share RSU grant - Stock Titan

10x Genomics BlogTXG (NASDAQ) Form 144: RSU grant 26,276 shares; insider sold 7,826 - Stock Titan

10x Genomics NewsAdam Taich files to sell 32,648 shares | TXG SEC Filing - Form 144 - Stock Titan

Merck & Co.Spotlight On: Five things to watch at ASCO - FirstWord Pharma

Novo NordiskBiopharma bites: CHMP backs oral Wegovy, Retro's financing, plus CVC's bid for Recordati - FirstWord Pharma

Endpoints NewsFDA clears Gilead's hepatitis D drug, four years after prior rejection

Clinical OMICsFungal Adjuvant Mannadjuvant Extends mRNA COVID-19 Vaccine Protections

Endpoints NewsGOP lawmaker asks Trump administration to curb China biotech deals

Clinical OMICsHow Colorectal Tumors Escape KRAS Inhibitors Identified

Clinical OMICsFDA Approves Datroway as First-Line Therapy for Triple-Negative Breast Cancer

FDA News ReleasesFDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection